IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 239 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,676,960 | -38.0% | 418,929 | -7.1% | 0.04% | -44.6% |
| Q3 2022 | $4,319,000 | -19.2% | 450,877 | -6.8% | 0.07% | -9.8% |
| Q2 2022 | $5,344,000 | -36.9% | 484,022 | -4.9% | 0.08% | -24.1% |
| Q1 2022 | $8,470,000 | -29.5% | 508,695 | -19.2% | 0.11% | -23.4% |
| Q4 2021 | $12,019,000 | -8.7% | 629,613 | +17.9% | 0.14% | -13.5% |
| Q3 2021 | $13,171,000 | -14.7% | 534,087 | -10.0% | 0.16% | -10.9% |
| Q2 2021 | $15,449,000 | -5.9% | 593,754 | +14.5% | 0.18% | -9.9% |
| Q1 2021 | $16,417,000 | -53.7% | 518,536 | -32.1% | 0.20% | -55.4% |
| Q4 2020 | $35,423,000 | +18.3% | 763,423 | -16.0% | 0.46% | -15.6% |
| Q3 2020 | $29,934,000 | +13.1% | 909,287 | -5.7% | 0.54% | +38.2% |
| Q2 2020 | $26,459,000 | -3.6% | 963,884 | +5.1% | 0.39% | -8.9% |
| Q1 2020 | $27,442,000 | +258.7% | 916,709 | +231.7% | 0.43% | +435.0% |
| Q4 2019 | $7,650,000 | – | 276,360 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |